PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES- LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67639-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)67639-5/fulltext
Title :
PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES- LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67639-5&doi=10.1016/S1098-3015(10)67639-5
First page :
Section Title :
Open access? :
No
Section Order :
223